Analysts Set Urogen Pharma (NASDAQ:URGN) PT at $33.29

Shares of Urogen Pharma (NASDAQ:URGN) have earned an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $33.2857.

URGN has been the subject of a number of research analyst reports. Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a report on Monday, March 2nd. D. Boral Capital reissued a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, January 21st.

Insider Buying and Selling at Urogen Pharma

In other news, insider Mark Schoenberg sold 7,373 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $145,174.37. Following the completion of the transaction, the insider owned 144,985 shares in the company, valued at $2,854,754.65. This trade represents a 4.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Jason Drew Smith sold 7,479 shares of Urogen Pharma stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $147,261.51. Following the completion of the sale, the general counsel directly owned 51,326 shares in the company, valued at $1,010,608.94. This trade represents a 12.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 4.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Urogen Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after buying an additional 486 shares in the last quarter. CWM LLC raised its holdings in shares of Urogen Pharma by 18.0% during the 3rd quarter. CWM LLC now owns 4,271 shares of the company’s stock worth $85,000 after acquiring an additional 650 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Urogen Pharma by 9.4% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 9,261 shares of the company’s stock valued at $127,000 after acquiring an additional 797 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Urogen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock valued at $258,000 after acquiring an additional 1,653 shares during the last quarter. Finally, Main Street Financial Solutions LLC grew its holdings in shares of Urogen Pharma by 8.2% in the second quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock valued at $356,000 after purchasing an additional 1,968 shares in the last quarter. 91.29% of the stock is owned by institutional investors.

Urogen Pharma Stock Up 5.3%

NASDAQ URGN opened at $18.94 on Thursday. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $30.00. The business has a 50-day moving average price of $19.81 and a 200-day moving average price of $20.74. The firm has a market cap of $922.00 million, a price-to-earnings ratio of -5.92 and a beta of 1.43.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Monday, March 2nd. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.12. The business had revenue of $37.84 million for the quarter, compared to the consensus estimate of $39.92 million. Research analysts expect that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.